Etao International Co., Ltd.

Etao International Co., Ltd.

ETAOF
Etao International Co., Ltd.US flagOther OTC
0.00
USD
- -
- -
512.00Market Cap
Etao International Co., Ltd.
ETAOF
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
FRC
10.09
10.98
Revenue per Share
-1.99
-169.64
Basic EPS, GAAP
-0.49
1.93
Free Cash Flow per Basic Share
- -
- -
Dividend per Share
-2.05
-171.7
Book Value per Share
-1.37
-1.34
Tangible Book Value per Share
5
5
Basic Weighted Avg Shares
53
58
Sales/Revenue/Turnover
-10.17
-1,269.63
Operating Margin (%)
2
2
Depreciation Expense
-11
-897
Net Income, GAAP
- -
- -
Effective Tax Rate (%)
-19.77
-1,544.4
Profit Margin (%)
-12
-8
Working Capital
6
5
LT Debt
154
-6
Total Equity
- -
- -
Return on Invested Capital (%)
- -
- -
Return on Capital (%)
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-103.88%
Free Cash Flow
- -
- -
-490.74%
Net Income, GAAP
- -
- -
8,404.67%
Sales/Revenue/Turnover
- -
- -
8.85%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
53
2022
- -
58
- -
- -
58
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
-1.99
2022
- -
- -
- -
- -
-169.64
2023
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Business
ETAO International Co., Ltd. (ETAOF) operates as a digital healthcare company that develops an integrated ecosystem encompassing online telemedicine, artificial intelligence diagnostics, big data evaluation, online insurance, pharmacy services, biotechnology solutions, offline hospitals, and specialty clinics including infertility treatment, orthopedic surgery, plastic surgery, primary care, and digital diabetes management. The company, incorporated in 2020 and headquartered in New York, New York with operations across North America, China, Canada, Latin America, and Australia, maintains a network of 12 hospitals, 30 clinics, and digital platforms serving over 5 million registered users. ETAO International delivers AI-driven precision medicine, OMO (online-merge-offline) healthcare, and cross-border networks powered by technologies such as cloud pharmacy transactions, EMR analysis, online consultations, and AI cancer screening. Recent strategic acquisitions include HiPatho for digital pathology, DiaCarta for precision diagnostics, and 6D Dental for AI dental imaging, contributing to over 12 global healthcare capability enhancements and unaudited 2024 consolidated revenue exceeding $150 million USD with pro forma 2025 projections surpassing $660 million USD. In March 2024, the company executed a 1-for-20 reverse share split, increased authorized shares, and altered its share capital structure. ETAO International targets Nasdaq relisting by Q4 2025 following Q1-Q3 2025 milestones in legal planning, acquisition finalization, regulatory approvals, and operational integration, supported by internal cash reserves, PIPE funding, and strategic equity partners focused on dental, AI medical technology, and U.S. healthcare assets.